false
0001460702
0001460702
2025-09-26
2025-09-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) September 26, 2025
QUALIGEN
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-37428 |
|
26-3474527 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification No.) |
| |
5857
Owens Avenue, Suite 300, Carlsbad, California 92008 |
|
| |
(Address
of principal executive offices)(Zip Code) |
|
Registrant’s
telephone number, including area code (760) 452-8111
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
stock (par value $0.001 per share) |
|
QLGN |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On
September 26, 2025, the Board of Directors (the “Board”) of Qualigen Therapeutics, Inc. (the “Company”) appointed
Kevi Chen to serve as an independent member of the Board, effective immediately. As of the date of this Current Report on Form 8-K, Mr.
Chen has not been appointed to any committees of the Board.
Kevin
Chen, 47, Independent Director. Kevin Chen is currently Chief Economist and CIO of Horizon Financial. Board member of
CurrenC Group (listed on Nasdaq), Australian Oilseeds Investments (listed on Nasdaq), Scage Future (EV truck company listed on Nasdaq),
Capitan Investment Ltd. (listed on Toronto Stock Exchange). Former board member of Infint Acquisition Corporation (listed on the NYSE).
Adjunct Associate Professor, New York University. A guest speaker at Harvard University, Fordham University, Pace University, and IESE
Business School. Former member of the Adjunct Advisory Committee and former Interim Head of the Private Sector Concentration program
of Ms. Global Affairs, New York University. Memeber of the Economic Club of New York. Life Member of the Council on Foreign Relations.
Fellow of the Foreign Policy Association. Member of the Bretton Woods Committee. Member of the Economic Club of Miami. Editorial Advisory
Board Member of the Global Commodity Applied Research Digest (GCARD) at JP Morgan Center for Commodities (JPMCC) at the University of
Colorado Denver Business School. Co-Chair of the New York Finance Forum. He was Senior Portfolio Manager, Credit Agricole/Amundi Asset
Management from Aug. 2008 to Oc. 2011. Director of Asset Allocation at Morgan Stanley August 2004 to August 2008. Manager at China Development
Bank, September 1998 to August 2000. PhD in Finance from the Financial Asset Management Engineering Center at University of Lausanne,
Switzerland at October 2004. Master’s degree in Finance, Center for Economic Research, Tilburg University in the Netherlands at
August 2001. B.A. degree in Economics from the Renmin University of China in Beijing, China, July 1998.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
Number |
|
Description |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
QUALIGEN
THERAPEUTICS, INC. |
| |
|
| Date:
September 29, 2025 |
By: |
/s/
Kevin A. Richardson II |
| |
|
Kevin
A. Richardson II |
| |
|
Chief
Executive Officer |
